tiprankstipranks
Advertisement
Advertisement

NXTC Stock Latest News

NextCure reports Q2 EPS ($2.80), consensus ($1.92)
The FlyNextCure reports Q2 EPS ($2.80), consensus ($1.92)
27d ago
NXTC
NextCure trading resumes
PremiumThe Fly
NextCure trading resumes
2M ago
NXTC
NextCure trading halted, volatility trading pause
PremiumThe Fly
NextCure trading halted, volatility trading pause
2M ago
NXTC
Analyst Initiates Buy on NextCure as Merger with Avere Positions AVR-001 for Well-Financed Late-Stage Development in Psoriasis and UC
PremiumRatings
Analyst Initiates Buy on NextCure as Merger with Avere Positions AVR-001 for Well-Financed Late-Stage Development in Psoriasis and UC
2M ago
NXTC
NextCure Announces Transformative All-Stock Merger With Avere
PremiumCompany Announcements
NextCure Announces Transformative All-Stock Merger With Avere
2M ago
8K
NXTC
Midday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat
PremiumThe FlyMidday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat
2M ago
GS
PM
Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That
Premium
TipRanks Newswire
Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That
2M ago
LLY
NXTC
Why Is Penny Stock NextCure (NXTC) Up Today?
Premium
Market News
Why Is Penny Stock NextCure (NXTC) Up Today?
2M ago
NXTC
NextCure, Avere Therapeutics enter definitive merger agreement
PremiumThe Fly
NextCure, Avere Therapeutics enter definitive merger agreement
2M ago
NXTC
NextCure, Avere Therapeutics enter definitive merger agreement
PremiumThe Fly
NextCure, Avere Therapeutics enter definitive merger agreement
2M ago
NXTC
NextCure Shareholders Approve Expanded Omnibus Incentive Plan
PremiumCompany Announcements
NextCure Shareholders Approve Expanded Omnibus Incentive Plan
2M ago
8K
NXTC
NextCure share weakness overdone, says Lucid Capital
PremiumThe Fly
NextCure share weakness overdone, says Lucid Capital
3M ago
NXTC
NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
PremiumThe FlyNextCure presents Phase 1 data for SIM0505 in gynecologic cancers
3M ago
NXTC
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data
Premium
Company Announcements
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data
3M ago
8K
NXTC
NextCure initiated with a Buy at Lucid Capital
Premium
The Fly
NextCure initiated with a Buy at Lucid Capital
4M ago
NXTC
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
PremiumThe Fly
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
4M ago
NXTC
NextCure initiates dose optimization portion of SIM0505 study
PremiumThe Fly
NextCure initiates dose optimization portion of SIM0505 study
4M ago
NXTC
NextCure granted Fast Track Designation for SIM0505 by FDA
PremiumThe Fly
NextCure granted Fast Track Designation for SIM0505 by FDA
5M ago
NXTC
NextCure trading resumes
PremiumThe Fly
NextCure trading resumes
6M ago
NXTC
NextCure trading halted, volatility trading pause
PremiumThe FlyNextCure trading halted, volatility trading pause
6M ago
NXTC
NextCure Updates ADC Pipeline Progress and Cash Runway
Premium
Company Announcements
NextCure Updates ADC Pipeline Progress and Cash Runway
7M ago
8K
NXTC
NextCure expects SIM0505 Phase 1 dose escalation data update in Q2
Premium
The Fly
NextCure expects SIM0505 Phase 1 dose escalation data update in Q2
7M ago
NXTC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >